Akums Drugs Pharmaceuticals Ltd vs Sun Pharma Advanced Research Company Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Akums Drugs & Pharmaceuticals Ltd is ₹ 552.2 as of 05 May 15:30 . The P/E Ratio of Akums Drugs & Pharmaceuticals Ltd changed from 21.5 on March 2025 to 0 on March 2022 . This represents a CAGR of -100.00% over 3 yearsThe P/E Ratio of Sun Pharma Advanced Research Company Ltd changed from -14 on March 2025 to 0 on March 2022 . This represents a CAGR of -100.00% over 3 years The Market Cap of Akums Drugs & Pharmaceuticals Ltd changed from ₹ 7469 crore on March 2025 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 3 yearsThe Market Cap of Sun Pharma Advanced Research Company Ltd changed from ₹ 5823 crore on March 2023 to ₹ 0 crore on March 2022 . This represents a CAGR of -100.00% over 5 years The revenue of Akums Drugs & Pharmaceuticals Ltd for the Dec '25 is ₹ 1193 crore as compare to the Sep '25 revenue of ₹ 1049 crore. This represent the growth of 13.72% The revenue of Sun Pharma Advanced Research Company Ltd for the Dec '25 is ₹ 8.45 crore as compare to the Sep '25 revenue of ₹ 7.87 crore. This represent the growth of 7.37% The ebitda of Akums Drugs & Pharmaceuticals Ltd for the Dec '25 is ₹ 162.96 crore as compare to the Sep '25 ebitda of ₹ 126.84 crore. This represent the growth of 28.48% The ebitda of Sun Pharma Advanced Research Company Ltd for the Dec '25 is ₹ -69 crore as compare to the Sep '25 ebitda of ₹ -65.71 crore. This represent the growth of 5.01% The net profit of Akums Drugs & Pharmaceuticals Ltd changed from ₹ 61.21 crore to ₹ 67.67 crore over 7 quarters. This represents a CAGR of 5.90% The net profit of Sun Pharma Advanced Research Company Ltd changed from ₹ -95.9 crore to ₹ -80.42 crore over 7 quarters. This represents a CAGR of -9.57% The Dividend Payout of Akums Drugs & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Sun Pharma Advanced Research Company Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Akums Drugs & Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the RoC. Alkums Drugs & Pharmas are a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
They are into sale of branded pharmaceutical formulations and manufacturing of Active Pharmaceutical Ingredients.
Some of the other services include formulation research and development, preparation and filing of regulatory dossiers into the Indian and global markets, and other testing services.
Some of manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation.

About Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems.
The Company works on innovation and new product development for global markets.
They undertake projects in research and technology for new chemical entities (NCE's) or new molecules, and novel drug delivery systems (NDDS). Sun Pharmaceutical Advanced Research Company Limited was incorporated on March 1, 2006 as an innovative and development company.
It commenced operations on March 22, 2006.
As per Scheme of Arrangement, the entire business undertaking of the Innovative Research & Development including Novel Drug Delivery System (NDDS) Division of Sun Pharmaceuticals Industries' Research & Development Undertaking was transferred and vested into the Company effective from February 28, 2007.

FAQs for the comparison of Akums Drugs & Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd

Which company has a larger market capitalization, Akums Drugs & Pharmaceuticals Ltd or Sun Pharma Advanced Research Company Ltd?

Market cap of Akums Drugs & Pharmaceuticals Ltd is 8,691 Cr while Market cap of Sun Pharma Advanced Research Company Ltd is 4,544 Cr

What are the key factors driving the stock performance of Akums Drugs & Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd?

The stock performance of Akums Drugs & Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Akums Drugs & Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd?

As of May 5, 2026, the Akums Drugs & Pharmaceuticals Ltd stock price is INR ₹552.2. On the other hand, Sun Pharma Advanced Research Company Ltd stock price is INR ₹140.05.

How do dividend payouts of Akums Drugs & Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd compare?

To compare the dividend payouts of Akums Drugs & Pharmaceuticals Ltd and Sun Pharma Advanced Research Company Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.